Westwood Salient Enhanced Energy Income ETF (NASDAQ: WEEI)

에 대한 최신 뉴스 Westwood Salient Enhanced Energy Income ETF (NASDAQ:WEEI)

Energy

Technology

Other

The Fund is an actively managed exchange-traded fund (ETF) that seeks to achieve its investment objectives by investing, under normal circumstances, at least 80% of its net assets (plus the amount of borrowings, if any, for investment purposes) in securities of Energy Companies (as defined below). The Fund invests primarily in equity securities of Energy Companies. The Fund may invest in Energy Companies of any size market capitalization. The Fund considers Energy Companies to include companies in the Global Industry Classification Standard (GICS) energy sector and companies in any other GICS sectors that derive at least 50% of their revenues or profits from exploration, development, production, gathering, transportation, processing, storing, refining, distribution, mining or marketing, of natural gas, natural gas liquids (including propane), crude oil, refined petroleum products, petrochemicals, electricity, coal, uranium, hydrogen or other energy sources, renewable energy production, renewable energy equipment, energy storage, carbon, carbon dioxide, carbon dioxide and fugitive methane (greenhouse gases) mitigation and management (i.e., providing services to other companies to reduce their greenhouse emissions, including transportation and underground storage of carbon dioxide and mitigation of methane leakage usually through direct capture such as in landfills), as well as electric transmission, distribution, storage and system reliability support. Energy Companies also include companies providing engineering, consulting and construction services that derive at least 50% of their revenues or profits from the above, all of which are selected by the Fund's investment adviser.

Exxon Mobil Corp.

Chevron Corp

Conocophillips

Schlumberger Ltd

Eog Resources

Marathon Petroleum

Phillips 66

Valero Energy Corp.

Hess Corp

Williams Cos Inc

Oneok Inc

Kinder Morgan In

Exxon Mobil Corp

Westwood Salient Enhanced Energy Income ETF

Analyst Color

Equities

Large Cap

News

Price Target

Reiteration

Analyst Ratings

Trading Ideas

iShares Dow Jones US Oil & Gas Exploration & Production Index Fund

WEEI

여러 분석가들은 기업 가치가 225억 달러에 달하는 전체 주식 거래에서 코노코필립스(NYSE:COP)가 마라톤 오일(NYSE:MRO)을 인수하는 거래에 대해 자신의 견해를 표명했다.어제 코노코필립스는 2024년 4분기부터 주당 보통 기본 배당금을 34% 증가한 0.78달러로 늘릴 것으로 예상한다고 밝혔다.

코노코필립스는 마라톤 오일 인수를 통해 수익성 향상과 자산 기반 강화 예상: 분석가들

Oshkosh Defense LLC, an Oshkosh Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSK#NYSE">OSK</a>) business, announced today that U.S. Army Contracting Command – Detroit Arsenal (ACC-DTA) has placed an order valued at $95 million on the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Foshkoshdefense.com%2Foshkosh-awarded-1-54-billion-fhtv-v-follow-on-contract%2F&amp;esheet=54231721&amp;newsitemid=20250401704484&amp;lan=en-US&amp;anchor=Family+of+Heavy+Tactical+Vehicle+%28FHTV%29+V+contract&amp;index=1&amp;md5=2c2b731e2e280e9b8608e131c2430e15">Family of Heavy Tactical Vehicle (FHTV) V contract</a>. The orders include the modernized, autonomy-ready Palletized Load System (PLS) A2.
The advanced driver assistance and autonomy-ready technologies of the PLS A2 promote significant improvements to Soldier safety and broadens battlefield awareness. By integrating by-wire and active-safety systems, the PLS A2 supports the Army's vision for a technology-enabled logistics force capable of executing missions in contested environments with reduced risk to the Warfighter. The flexible architecture of the heavy fleet allows significant room for growth and the integration of new technology to support unit innovation as both threats and requirements evolve.

Contracts

Oshkosh Defense Announces The U.S. Army Contracting Command – Detroit Arsenal Has Placed An Order Valued At $95M On The Family Of Heavy Tactical Vehicle V Contract

BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company developing transformative treatments for complex neurological disorders, including Autism Spectrum Disorder (ASD), brain cancers, and Alzheimer's disease, and a subsidiary of Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>), proudly announces the publication of breakthrough research by its Chief Scientific Officer, Prof. Haitham Amal, in Translational Psychiatry, a peer-reviewed medical journal published by Nature Publishing Group. The article, which is titled, "Shared Early Molecular Mechanisms Revealed in P301S and 5xFAD Alzheimer's Disease Mouse Models," presents compelling evidence of a novel mechanism in the early stages of Alzheimer's disease (AD), offers new hope for the development of effective therapies for this devastating condition. A copy of the article is available on Translational Psychiatry website at (<a href="https://www.globenewswire.com/Tracker?data=YIX3LNtAbY5gepMGAJHZohMI6bdP2Jv23VO5pTYF99PKl3Durv0ZjdTZe49uqRJGBxEHTIwXNTTkM9j52nyjIHGiE5d5TcY9Ow9bScFwN7pvXIGM8j2VqBtK4NGI8Dwp">click here</a>).
Alzheimer's disease is one of the most common and costly neurodegenerative disorders globally, affecting over 55 million people and imposing a staggering economic burden exceeding $1 trillion annually. Beyond its financial toll, AD devastates families, progressively eroding the identity and autonomy of those afflicted. Despite decades of research, there remains no truly effective treatment capable of halting or reversing the disease's progression.
The research discussed in the article identifies significant disruptions in nitric oxide (NO)-related pathways, particularly in S-nitrosylation, a key post-translational modification mediated by NO. The research demonstrates early and consistent molecular changes across two established AD mouse models, highlighting the role of nitrosative stress, impaired neurotransmission, and mTOR hyperactivation. Importantly, the data suggest that targeted inhibition of NO production may serve as a promising therapeutic strategy in early-stage Alzheimer's disease.
"The results of this study validate a key component of our scientific vision," said Prof. Amal. "We have demonstrated, for the first time, a shared mechanism in Alzheimer's models rooted in nitric oxide dysregulation. These results strengthen our confidence in the potential of NO modulation as a therapeutic approach and further establish the robustness of our CNS drug development platform."
"NeuroNOS is a young and radically innovative company, built to think differently and move fast," added Amir Avniel, CEO of NeuroNOS. "In a remarkably short time, we have transitioned from scientific vision to tangible reality—decoding one of the most critical mechanisms in brain diseases and constructing a drug development platform around it. We are already in advanced stages of formulation development and manufacturing, preparing for clinical trials. The brain disease arena is in dire need of breakthroughs, and we have embraced the unique mission to lead this innovative development of brain therapeutics."

Biotech

General

XAIR

NeuroNOS Releases Research Publication By Its CSO Demonstrating Mechanism Of Action In Alzheimer's Disease

HC Wainwright &amp; Co. analyst Ed Arce maintains Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) with a Buy and raises the price target from $4 to $7.5.

UNCY

HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Raises Price Target to $7.5

Brookfield Asset Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/BAM#TSX">BAM</a>) ("Brookfield") and Angel Oak Companies ("Angel Oak"), a leading asset manager delivering innovative mortgage and consumer products, today announced that they have entered into an agreement in which Brookfield will acquire a majority ownership stake in Angel Oak and offer its investors access to the firm's residential mortgage credit strategies. Angel Oak joins Brookfield as part of the firm's $317 billion credit business, aligning with Brookfield's broader strategy to partner with best-in-class credit managers alongside its direct investment platform.

TSX:BAM

Brookfield Asset Management And Angel Oak To Enter Into Strategic Partnership In Which Brookfield Will Acquire A Majority Ownership Stake In Angel Oak And Offer Its Investors Access To The Firm's Residential Mortgage Credit Strategies

Guidance

Novagold Says Well-prepared To Fund Its Share Of Activities For Next Two Years At Current Spending Levels; FY25 Budgeted Cash Expenditures At $37.5M

CARLSBAD, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLGN#NASDAQ">QLGN</a>) (the "Company") announced today they have entered a non-binding Memorandum of Understanding (MOU) to acquire Marizyme (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRZM#OTC">MRZM</a>).
Qualigen and Marizyme have entered an MOU dated March 28, 2025. This is the logical next step in acquiring Marizyme, following on our co-marketing agreement established in 2024. Upon completion of full due diligence, we will proceed with the final structure and deal terms which will be subject to shareholder approval following the filing of an S4.
There can be no assurance that any transaction will be completed or that definitive agreements will be executed.
Marizyme's DuraGraft is an FDA cleared platform technology in the Coronary Artery Bypass Graft (CABG) market. The CABG market is over $10 billion in revenue annually. It is estimated there are more than 500,000 CABG surgeries performed every year in the US. In CABG surgery, saphenous vein graft (SVG) failure rates are a concern, with approximately 50% failing within 5 to 10 years, and between 20-40% failing within the first year.&nbsp;DuraGraft has the potential to change the landscape of cardiac care by preventing oxidative damage, therefore slowing the progression of vein graft failure. DuraGraft has the potential to increase hospital savings through the reduction of repeat procedures and hospital stays.
"We are extremely excited to bring Marizyme into the Qualigen Therapeutics company. Having an already FDA cleared product in our portfolio of businesses will provide the company with rapid revenue growth beginning in 2025. We look forward to providing further updates to shareholders as we make progress on completing diligence and finalizing terms of the transaction "stated Kevin Richardson II, Chief Executive Officer of Qualigen.

MRZM

Qualigen Therapeutics, Inc. - Common Stock

QLGN

Qualigen Enters $10B Coronary Artery Bypass Graft Market With Non-Binding MOU To Acquire Marizyme

Novagold Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NG#AMEX">NG</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by 25 percent.&nbsp;

Earnings

Earnings Beats

Novagold Resources Q1 2025 GAAP EPS $(0.03) Beats $(0.04) Estimate

HC Wainwright &amp; Co. analyst Ed Arce reiterates Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) with a Buy and maintains $6 price target.

TLPH

HC Wainwright & Co. Reiterates Buy on Talphera, Maintains $6 Price Target

In the preceding three months, 20 analysts have released ratings for Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $183.15, a high estimate of $220.00, and a low estimate of $135.00. Highlighting a 6.5% decrease, the current average has fallen from the previous average price target of $195.88. 
<img src="https://www.benzinga.com/files/images/story/2025/1743508864_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Oracle. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Curtis Shauger</td>
<td>WestPark Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$195.00</td>
<td>-</td>
</tr>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$190.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Brett Huff</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$167.00</td>
<td>-</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$194.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$170.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$175.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$150.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$135.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jackson Ader</td>
<td>Keybanc</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Thomas Blakey</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$202.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$185.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$220.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Thomas Blakey</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$214.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Oracle. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Oracle compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Oracle's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Oracle's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ORCL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Oracle analyst ratings.</a>
<h2>About Oracle</h2>
Oracle provides enterprise applications and infrastructure offerings around the world through a variety of flexible IT deployment models, including on-premises, cloud-based, and hybrid. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system, which is commonly used for running online transaction processing and data warehousing workloads. Besides database systems, Oracle also sells enterprise resource planning, or ERP, customer relationship management, or CRM, and human capital management, or HCM, applications. Today, Oracle has more than 159,000 full-time employees in over 170 countries.
<h3>Oracle's Economic Impact: An Analysis</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining Oracle's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 6.4% as of 28 February, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Oracle's net margin excels beyond industry benchmarks, reaching 20.78%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 19.27%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Oracle's ROA stands out, surpassing industry averages. With an impressive ROA of 1.9%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 5.75, caution is advised due to increased financial risk.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ORCL

A Glimpse Into The Expert Outlook On Oracle Through 20 Analysts

7 analysts have shared their evaluations of Keros Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Keros Therapeutics and provided 12-month price targets. The average target is $28.57, accompanied by a high estimate of $41.00 and a low estimate of $15.00. This current average represents a 35.27% decrease from the previous average price target of $44.14. 
<img src="https://www.benzinga.com/files/images/story/2025/1743508856_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Keros Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Andreas Argyrides</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$41.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Andreas Argyrides</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$23.00</td>
<td>$63.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Keros Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Keros Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Keros Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Keros Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/KROS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Keros Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Keros Therapeutics: A Closer Look</h2>
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
<h3>Keros Therapeutics: Financial Performance Dissected</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Keros Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 2027.27%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -1513.02%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Keros Therapeutics's ROE excels beyond industry benchmarks, reaching -8.34%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Keros Therapeutics's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.7% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Keros Therapeutics's debt-to-equity ratio is below the industry average at 0.03, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KROS

Forecasting The Future: 7 Analyst Projections For Keros Therapeutics

<a href="https://www.jabil.com/news/jabil-launches-1.6t-pluggable-transceiver.html" title="https://www.jabil.com/news/jabil-launches-1.6t-pluggable-transceiver.html">https://www.jabil.com/news/jabil-launches-1.6t-pluggable-transceiver.html</a>

Jabil Launches 1.6T Pluggable Transceiver To Support Growing Demand For Intra-Data Center And AI Connectivity

In the latest quarter, 6 analysts provided ratings for BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $152.57, a high estimate of $172.00, and a low estimate of $139.00. Observing a 2.32% increase, the current average has risen from the previous average price target of $149.11. 
<img src="https://www.benzinga.com/files/images/story/2025/1743508847_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of BioNTech among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$145.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$145.00</td>
<td>-</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$139.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>John Newman</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$171.44</td>
<td>$171.44</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$143.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$172.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to BioNTech. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of BioNTech compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for BioNTech's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into BioNTech's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BNTX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on BioNTech analyst ratings.</a>
<h2>Delving into BioNTech's Background</h2>
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
<h3>BioNTech's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Negative Revenue Trend: Examining BioNTech's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -19.54% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: BioNTech's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 21.81%, the company may face hurdles in effective cost management.
Return on Equity (ROE): BioNTech's ROE excels beyond industry benchmarks, reaching 1.35%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): BioNTech's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.16% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.01, BioNTech adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BNTX

BioNTech Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

During the last three months, 4 analysts shared their evaluations of Genuine Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $131.75, a high estimate of $155.00, and a low estimate of $114.00. This current average reflects an increase of 1.35% from the previous average price target of $130.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1743508836_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Genuine Parts. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kate McShane</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$114.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$133.00</td>
<td>$129.00</td>
</tr>
<tr>
<td>Greg Melich</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$125.00</td>
<td>$128.00</td>
</tr>
<tr>
<td>Chris Dankert</td>
<td>Loop Capital</td>
<td>Announces</td>
<td>Buy</td>
<td>$155.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Genuine Parts. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Genuine Parts compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Genuine Parts's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Genuine Parts's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GPC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Genuine Parts analyst ratings.</a>
<h2>Get to Know Genuine Parts Better</h2>
Genuine Parts sells aftermarket automotive parts (about 60% of sales) and industrial products (40% of sales) in the United States and internationally. The automotive segment primarily acts as a distributor to its network of 9,800 global retail locations of which about two thirds are independently owned and operated. We estimate Genuine serves around 6,000 retail locations in the US operating under the Napa Auto Parts brand, with about 80% of end market sales derived from professional customers. Its industrial segment, primarily operating under the Motion banner in the United States, serves as a leading distributor of bearings, power transmission, and other industrial products to more than 200,000 maintenance, repair, and original equipment manufacturer customers.
<h3>Genuine Parts's Financial Performance</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining Genuine Parts's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.3% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Genuine Parts's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 2.31%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.95%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.67%, the company showcases effective utilization of assets.
Debt Management: Genuine Parts's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.32, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Genuine Parts: 4 Analysts Share Their Views

Ratings for BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $66.11, a high estimate of $86.00, and a low estimate of $55.00. This current average represents a 0.21% decrease from the previous average price target of $66.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1743508829_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of BlackLine's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>William Jellison</td>
<td>DA Davidson</td>
<td>Announces</td>
<td>Buy</td>
<td>$58.00</td>
<td>-</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$70.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Terry Tillman</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$55.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$60.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$58.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Koji Ikeda</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Maintains</td>
<td>Buy</td>
<td>$73.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$86.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to BlackLine. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of BlackLine compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into BlackLine's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on BlackLine analyst ratings.</a>
<h2>Unveiling the Story Behind BlackLine</h2>
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close &amp; consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.
<h3>Financial Milestones: BlackLine's Journey</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining BlackLine's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.82% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 33.29%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): BlackLine's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 13.85%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): BlackLine's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.21%, the company showcases efficient use of assets and strong financial health.
Debt Management: BlackLine's debt-to-equity ratio stands notably higher than the industry average, reaching 2.05. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where BlackLine Stands With Analysts

DA Davidson analyst William Jellison initiates coverage on BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) with a Buy rating and announces Price Target of $58.

Initiation

DA Davidson Initiates Coverage On BlackLine with Buy Rating, Announces Price Target of $58

Across the recent three months, 12 analysts have shared their insights on Kohl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">2</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $9.85, a high estimate of $13.00, and a low estimate of $5.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 24.23%. 
<img src="https://www.benzinga.com/files/images/story/2025/1743508819_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Kohl's is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Sell</td>
<td>$5.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Kimberly Greenberger</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$8.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Mark Altschwager</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$10.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$9.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$13.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$11.25</td>
<td>$13.00</td>
</tr>
<tr>
<td>Randal Konik</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$12.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Kohl's. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Kohl's compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Kohl's's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Kohl's's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/KSS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Kohl's analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Kohl's</h2>
Kohl's operates about 1,150 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also has a large digital sales operation. Women's apparel is Kohl's largest category, having generated 25% of its 2024 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
<h3>Unraveling the Financial Story of Kohl's</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Kohl's's revenue growth over 3 months faced difficulties. As of 31 January, 2025, the company experienced a decline of approximately -9.39%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Kohl's's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 0.89%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.26%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Kohl's's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.34%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Kohl's's debt-to-equity ratio stands notably higher than the industry average, reaching 1.88. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Kohl's's Future

Are you a passive income investor looking for a stock that can still pay dividends in a recession? You might be surprised to learn that mortgage real estate investment trust AGNC Investment (NASDAQ:<a href="https://www.benzinga.com/quote/AGNC"> AGNC</a>) has paid investors a<a href="https://www.benzinga.com/25/02/43445680/wall-streets-most-accurate-analysts-spotlight-on-3-financial-stocks-with-over-13-dividend-yields"> double-digit dividend</a> since 2022 . Keep reading to find out why this stock could be well-positioned to boost your portfolio returns during a downturn.
AGNC combines investor contributions and leveraged debt, or loans,&nbsp; to buy agency-backed mortgage-backed securities portfolios. The investor profits are generated through the REIT's ability to borrow money at lower interest rates than the loans in the portfolio are charging the homeowners. So, If AGNC borrows money at 4.5% to buy a portfolio of MBS at 7% APR, AGNC makes a 2.5% annual profit.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
</ul>
That's not a massive return, but AGNC's careful use of leverage allows it to multiply returns by acquiring very large portfolios. A theoretical 2.5% return on tens of thousands of mortgages could still result in a healthy dividend for AGNC investors. AGNC's leadership team also employs a combination of short-term hedging and careful planning to protect themselves against higher borrowing costs.
It's no secret that high interest rates eat into mortgage <a href="https://www.benzinga.com/money/best-reits">REIT profits</a>. That reality also explains why AGNC investors could potentially profit from a recession. Why? The Federal Reserve knows that maintaining the flow of capital is a time-tested way of blunting a recession's effect on the economy. That means it will likely halt interest rate increases for as long as the threat of a recession exists.
Trending: <a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a>
It may also lower interest rates if there is a severe recession. That could result in even higher returns for AGNC investors. AGNC's website notes that<a href="https://agnc.com/portfolio/"> 98% of its MBS portfolios</a> are agency-backed. This means that in addition to having collateral securing the MBS in AGNC's portfolio, AGNC offers the added security of having loans backed up by Fannie Mae and Freddie Mac.&nbsp;
It's also worth noting that AGNC was formed in 2008. This mortgage REIT navigated the Great Financial Crisis and the COVID-19 pandemic and continues delivering for investors. According to the<a href="https://agnc.com/performance/"> company's website</a>, AGNC has delivered an average annual return of 10% since 2008.
See Also: This platform is reshaping how you invest in private companies —<a href="https://www.benzinga.com/money/kingscrowd-adv"> and you can be a part of it for $0.18 per share</a>
Annual returns in the double-digit range are not the only factors adding to AGNC's potential appeal. It pays monthly dividends, not quarterly like many other REITs or passive income stocks. Those monthly payments will help passive income investors manage their cash flow more effectively. AGNC is currently paying a very attractive<a href="https://www.benzinga.com/quote/AGNC/dividends"> 14.75% dividend</a> on its $9.83 share price.
That translates to $1.44 per share. If the economy continues experiencing turbulence, the likelihood of a long-term pause in rate increases, or even rate cuts, increases. Either scenario could benefit AGNC shareholders and lead to increased monthly returns. That doesn't mean there is no risk. The probability of mass defaults on AGNC portfolio assets would increase during a severe recession. With that caveat, AGNC has proven its ability to weather economic downturns.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
</ul>

Personal Finance

AGNC Pays A 14.75% Dividend And May Be Perfectly Positioned To Resist A Recession

HC Wainwright &amp; Co. analyst Robert Burns maintains BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) with a Buy and lowers the price target from $150 to $145.

HC Wainwright & Co. Maintains Buy on BioNTech, Lowers Price Target to $145

Dada Nexus Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DADA#NASDAQ">DADA</a>, "Dada" or the "Company"))), China's leading local on-demand retail and delivery platform, today announced that it has entered into an Agreement and Plan of Merger (the "Merger Agreement") with JD Sunflower Investment Limited, a British Virgin Islands&nbsp;company ("Parent") and JD Sunflower Merger Sub Limited, a Cayman Islands company and a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub will merge with and into the Company, with the Company continuing as the surviving company and becoming a wholly owned subsidiary of Parent (the "Merger"). Parent is wholly owned by JD.com, Inc. ("JD").
At the effective time of the Merger (the "Effective Time"), each American Depository Share of the Company (each, an "ADS"), representing four ordinary shares of the Company, par value US$0.0001 each (each, a "Share"), issued and outstanding immediately prior to the Effective Time, other than ADSs representing the Excluded Shares (as defined in the Merger Agreement), together with the Shares represented by such ADSs, will be cancelled and cease to exist in exchange for the right to receive US$2.0 in cash per ADS without interest, and each Share issued and outstanding immediately prior to the Effective Time, other than the Excluded Shares, the Dissenting Shares (as defined in the Merger Agreement) and Shares represented by ADSs, will be cancelled and cease to exist in exchange for the right to receive US$0.5 in cash per Share without interest.
The merger consideration represents a premium of approximately 42% to the closing price of the ADSs on January 24, 2025, the last trading day before the Company received the preliminary non-binding proposal letter from JD.

DADA

Dada Enters Into Definitive Agreement For "Going Private" Transaction With JD Sunflower Investment; Each ADS Representing 4 Ordinary Shares Will Be Cancelled In Exchange For $2.00 In Cash Per ADS, While Each Outstanding Share Will Be Cancelled In Exchange For $0.50 In Cash Per Share, With All Excluded Shares And Dissenting Shares Remaining Unaffected.

IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) shares are trading higher in the premarket session on Tuesday following the announcement of a<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44581701/ionq-announces-global-availability-of-forte-enterprise-through-amazon-braket-and-ionq-quantum-clou" rel="noreferrer noopener"> significant milestone in quantum computing.</a>
The company has officially made its flagship quantum computer, IonQ Forte Enterprise, available to global customers through Amazon Braket and the IonQ Quantum Cloud.
Amazon Braket is a fully managed AWS service that helps researchers, scientists, and developers start using quantum computing.&nbsp;
The collaboration with AWS allows customers worldwide to access the cutting-edge IonQ Forte Enterprise, a quantum system capable of #AQ36 performance.
This advancement opens new possibilities for industries such as life sciences, financial services, manufacturing, and pharmaceuticals to leverage quantum computing for solving complex challenges and creating real-world impact.
Also recently, Benchmark analyst David Williams reiterated IonQ with a Buy and $45&nbsp;price forecast.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/04/44582215/chinas-xpeng-clocks-record-q1-ev-sales-deliveries-surge-3-6x" rel="noreferrer noopener">China&#8217;s XPeng Clocks Record Q1 EV Sales, Deliveries Surge 3.6X</a>
Niccolo de Masi, President and CEO of IonQ, highlighted that the goal of the launch is to bring quantum technologies into the hands of developers, enabling them to create innovative commercial applications.
&#8220;IonQ&#8217;s goal is to get our quantum technologies into the hands of developers so they can build and develop new commercial applications to solve some of today&#8217;s most complex problems,&#8221; Masi added.
IonQ Forte Enterprise is designed with a rack-mounted form factor and optimized for energy efficiency and modern data center environments. The move builds on previous successes, such as Ansys using IonQ Forte to enhance the design of life-saving medical devices.
With this global availability, IonQ continues to expand its global data center footprint, which now includes Washington, D.C., Seattle, and Basel, Switzerland.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, IONQ stock has gained over 120% in the past year. Investors can gain exposure to the stock via&nbsp;Defiance Daily Target 2X Long IONQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONX#NASDAQ">IONX</a>).
Price Action: IONQ shares are trading higher by 1.86% to $22.48 premarket at last check Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/03/44568964/amd-powers-oracle-cloud-with-new-epyc-chips-promising-major-boost-in-performance" target="_blank" rel="noreferrer noopener">AMD Powers Oracle Cloud With New Epyc Chips Promising Major Boost In Performance</a></li>
</ul>
Image via Shutterstock.

Markets

Movers

IONQ

IONX

What's Going On With IonQ Stock Today?

Dividends

Press Releases

Westwood Announces Monthly Income Distributions for Westwood Salient Enhanced Midstream Income ETF (MDST) and Westwood Salient Enhanced Energy Income ETF (WEEI)

Westwood Holdings Group, Inc. Reports Second Quarter 2024 Results

Management

Westwood Hires Chris Doran as  Head of ETF Distribution & National Accounts

MDST

여러 분석가들은 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/39071635/conocophillips-marathon-deal-analyst-sees-short-term-pain-long-term-gain" target="_blank" rel="noreferrer noopener">기업 가치가 225억 달러</a>에 달하는 전체 주식 거래에서 코노코필립스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>)가 마라톤 오일(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRO#NYSE">MRO</a>)을 인수하는 거래에 대해 자신의 견해를 표명했다.
어제 코노코필립스는 2024년 4분기부터 주당 보통 기본 배당금을 34% 증가한 <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">0.78</a>달러로 늘릴 것으로 예상한다고 밝혔다.
첫 해에 70억 달러 이상(독립적으로 50억 달러 이상)의 주식을 매입하고 <a href="https://www.benzinga.com/markets/equities/24/05/39061149/conocophillips-acquires-marathon-oil-in-all-stock-deal-at-14-7-premium-details" target="_blank" rel="noreferrer noopener">첫 3년 동안</a> 200억 달러 이상의 주식을 재매입하는 것을 목표로 하고 있다.
트루이스트 증권의 분석가 닐 딩만(Neal Dingmann)은 마라톤 오일(MRO)의 주식이 여러 분기 동안 코노코필립스(COP)의 주식에 비해 눈에 띄게 할인된 가격으로 거래되었기 때문에 모든 지표에 대한 즉각적인 증가를 고려할 때 이번 거래를 긍정적으로 보고 있다고 썼다.
이 분석가는 이번 거래로 양질의 면적이 추가되어 코노코필립스가 바켄(Bakken) 및 이글 포드(Eagle Ford)의 가장 큰 자산 보유자 중 하나가 되었다고 썼다.
딩만은 코노코필립스가 잠재적으로 총 생산량을 유지할 가능성이 있지만 결합 활동을 둔화시킬 것으로 예상한다. 이 분석가는 마라톤 오일과의 이 거래에 다른 회사가 등장할 가능성은 거의 없다고 썼다.
딩만 분석가는 이후 160달러의 <a href="https://www.benzinga.com/quote/COP/analyst-ratings" target="_blank" rel="noreferrer noopener">목표 주가</a>에서 매수 평가를 재확인했다.
J.P.모건의 분석가인 아룬 자야람(Arun Jayaram)은 이번 인수 거래가 FCF 및 실적 지표(2025년 FCF 수익률 0.5% 증가, P/E 0.7배 감소)에서 증가하고 5억 달러의 시너지 효과(세전 G&amp;A/운영 지출 4억 달러, 자본금 1억 달러)를 제공할 것이라 예상했다.
이 분석가는 배당 인상에 대해 언급하면서 증분 기본 배당이 특별 배당을 대체할 것이라고 썼다.
자야람은 MRO가 유기적 개선과 2022년 말 30억 달러 규모의 엔사인(Ensign) 거래를 통해 재고 갱신에 대해 실용적인 접근 방식을 취했지만 시간이 지남에 따라 재고 갱신을 처리하기 위해 추가 조치를 취해야 한다고 말했다.
BMO 캐피털 마켓의 분석가인 필립 융워스(Phillip Jungwirth)는 COP에 대해 시장수익률 상회(Outperform) 등급과 135달러 목표 가격을 제시하며 이번 인수가 재정적으로 이익이 되고 경쟁력 있는 공급 비용으로 코노코필립스의 L48 포지션(바켄/이글 포드)을 강화한다고 썼다.
융워스는 마라톤의 강력한 자본 효율성이 자본을 놓고 경쟁해야 하며 이번 거래로 코노코필립스의 기업 FCF 손익분기점이 낮아질 것이라고 덧붙였다.
이 분석가는 코노코필립스의 2025년 EPS가 스트립 및 주당 현금 흐름에서 6% 증가하고 주당 FCF가 각각 5%와 ~9% 더 높을 것으로 추정한다.
관련 기사 : <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/39071635/conocophillips-marathon-deal-analyst-sees-short-term-pain-long-term-gain" target="_blank" rel="noreferrer noopener">코노코필립스의 마라톤 인수 거래: 단기적으로는 고통, 장기적으로는 이득</a>
미즈호의 한 분석가는 COP에 대해 중립적인 평가를 내리고, 이 기업의 주가에 대해 142달러의 가격 목표를 제시했다. 또한 이번 거래로 COP의 미국 셰일 포트폴리오에는 20억 배럴 이상의 오일 상당 비축, 2,000개의 위치, 그리고 1,000개 이상의 굴절(Refrac) 기회가 추가되었음에도, 이번 거래가 COP를 더 낫게 만든다는 것에 대해 걱정을 드러냈다.
이 분석가는 2019년 이후 두 회사가 모두 동종 기업들에 비해 웰 생산성 측면에서 뛰어난 성과를 보였지만, COP는 특히 바켄과 이글 포드에서 MRO보다 큰 이점을 가지고 있다고 덧붙였다.
투자자들은 IShares U.S. Oil &amp; Gas Exploration &amp; Production ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/IEO#BATS">IEO</a>)와 Westwood Salient Enhanced Energy Income ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEEI#NASDAQ">WEEI</a>)를 통해 COP에 노출될 수 있다.
주가 움직임: 목요일 코노코필립스의 주가는 1.42% 하락 113.58달러에 마감했다.

Comments

Westwood Salient Enhanced Energy Income ETF

뉴스

에 대한 최신 뉴스 Westwood Salient Enhanced Energy Income ETF (NASDAQ:WEEI)

목요일, 5월 30, 2024

뉴스

파트너 / 기고자

벤징가 글로벌